|
|
||||||||
1 Department of Physiology and Developmental Biology, Brigham Young University, Provo, Utah 84602; and 2 Division of Molecular Physiology, Dundee University, Wellcome Trust Biocentre, Dundee DD1 5EH, Scotland, United Kingdom
| |
ABSTRACT |
|---|
|
|
|---|
AMP-activated protein kinase
(AMPK) consists of three subunits:
,
, and
. Two isoforms
exist for the
-subunit (
1 and
2), two
for the
-subunit (
1 and
2), and three
for the
-subunit (
1,
2, and
3). Although the specific roles of the
- and
-subunits are not well understood, the
-subunit isoforms contain
the catalytic site and also the phosphorylation/activation site for the
upstream kinase. This study was designed to determine the role of
thyroid hormones in controlling expression levels of these AMPK
subunits and of one downstream target, acetyl-CoA carboxylase (ACC), in muscle. AMPK subunit and ACC levels were determined by Western blots in
control rats, in rats given 0.01% propylthiouracil (PTU) in drinking
water for 3 wk, and in rats given 3 mg of thyroxine and 1 mg of
triiodothyronine per kilogram chow for 1 or 3 wk. In gastrocnemius
muscle, all isoforms of AMPK subunits were significantly increased in
rats given thyroid hormones for 3 wk vs. those treated with PTU.
Similar patterns were seen in individual muscle types. Expression of
muscle ACC was also significantly increased in response to 3 wk of
treatment with excess thyroid hormones. Muscle content of malonyl-CoA
was elevated in PTU-treated rats and depressed in thyroid
hormone-treated rats. These data provide evidence that skeletal muscle
AMPK subunit and ACC expression is partially under the control of
thyroid hormones.
malonyl-CoA; propylthiouracil; thyroxine; triiodothyronine
| |
INTRODUCTION |
|---|
|
|
|---|
AMP-ACTIVATED PROTEIN
KINASE (AMPK) is an enzyme consisting of three subunits:
,
, and
(12, 13, 42, 45). Two isoforms exist for the
-subunit (
1 and
2), two for the
-subunit (
1 and
2), and three for the
-subunit (
1,
2, and
3).
Although the specific roles of the
- and
-subunits are not well
understood, the
-subunit isoforms contain the catalytic site and
also the phosphorylation/activation site for the upstream kinase
(AMPKK). In humans, the genes for these isoforms are located on
chromosomes 1, 2, 5, 7, and 12 (see
http://us.expasy.org/cgi-bin/niceprot; http://bioinfo.weizmann. ac.il/cards-bin/carddisp and Refs.
2 and 32). The locus for the gene for the
1-subunit (5p12) is different from that for the
2-subunit (1p31). The gene for the
1-subunit is located at 12q24.1 and the gene for the
2-subunit at 1q12-q21. The positions for the
1-,
2-, and
3-subunit
isoforms are 12q13.1, 7q36, and 2q35, respectively.
Exceptionally large changes (200-fold) can occur in the activity of
AMPK, inasmuch as it is regulated by covalent modification and
allosteric mechanisms (6, 12, 13). It is phosphorylated (threonine 172 of the
-subunit) and, thereby, activated by an upstream kinase, AMPKK, which is activated allosterically by 5'-AMP (14, 33). The phosphorylated AMPK is also allosterically
activated by increases in 5'-AMP and inhibited by high concentrations
of ATP and phosphocreatine (12, 13, 28, 42, 45). Any
perturbation that will increase 5'-AMP or decrease phosphocreatine or
ATP will result in activation of the kinase. The most common natural
conditions when this occurs include muscle contraction and hypoxia
(12, 13, 34, 39, 42, 45). Thus the enzyme can be thought of as a sensitive energy monitor in the muscle fiber (12, 13, 40,
42, 45).
The actions of AMPK appear to be designed to prevent ATP depletion in the muscle fiber. Thus AMPK phosphorylates and inactivates acetyl-CoA carboxylase (ACC), resulting in a decrease in malonyl-CoA, relieving inhibition of carnitine palmitoyltransferase (CPT) and allowing fatty acid oxidation to proceed (21, 42, 44-46). Accumulating evidence indicates that AMPK stimulates glucose transport into the muscle by causing translocation of GLUT-4 from microvesicles into the muscle sarcolemma and T tubules (21, 42). Sensitivity of muscle to insulin has recently been discovered to be influenced by prior AMPK activation (8). With chronic activation of AMPK over a period of several days, there is an increase in expression of GLUT-4 and hexokinase, apparently due to an enhancement of transcription (24, 42, 52). Recently, insulin receptor substrate-1 has been shown to be a target for AMPK (15). Mitochondrial enzymes of the citric acid cycle and electron transport chain also increase in response to chronic activation of muscle AMPK by injection of 5-aminoimidazole-4-carboxamide-riboside into rats (42).
Despite its apparent central role in regulation of fatty acid
oxidation, glucose uptake, insulin sensitivity, and GLUT-4 expression in muscle, little is known regarding the control of expression of
subunit isoforms of AMPK in muscle. In a recent study on the effect of
endurance training on AMPK subunit expression, it appears that only
3-subunit expression in fast-twitch high-oxidative muscle (type IIa fibers) is increased (3-fold) by endurance training (7). Previous studies have clearly demonstrated that
mitochondrial enzymes, GLUT-4, and hexokinase levels in muscle increase
with chronic treatment of rats with excess thyroid hormones (43, 47). The mechanisms of these effects are not completely
understood. Likewise, many of the effects of thyroid hormones on fat
metabolism and body composition are not entirely explained with
available data. It seemed reasonable that AMPK, which also appears to
be involved in control of expression of several muscle proteins and of
carbohydrate and fat metabolism, may be governed in part by the thyroid
state. This study was designed to test the hypothesis that thyroid
hormones influence AMPK expression in muscle.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Animal care. All procedures were approved by the Institutional Animal Care and Use Committee of Brigham Young University. Male Sprague-Dawley rats (Sasco, Wilmington, MA) were housed in individual cages in a room lighted from 6 AM to 6 PM. Rats were fed powdered Harlan Teklad rodent diet (Madison, WI). Rats weighed an average of 205 ± 2 g at the beginning of treatments. Rats were divided into four treatment groups. The first group (controls) received powdered food and water ad libitum. The second group received 0.01% propylthiouracil (PTU) in drinking water for 3 wk for the purpose of inhibiting thyroid hormone synthesis. This dose of PTU results in marked hypertrophy of the thyroid (54.3 ± 9.1 vs. 14.2 ± 0.5 mg in controls). The third group was provided with powdered Harlan Teklad rodent diet containing 3 mg of thyroxine and 1 mg of 3,5,3'-triiodothyronine per kilogram for 3 wk (T21d). The fourth group was given the same amount of thyroid hormones in their food but only for 1 wk (T7d). This dose has previously been shown to increase mitochondrial enzymes in liver and muscle and to increase heart weight (43, 47).
On the afternoon before the rats were killed, they were given 16 g of rat chow. After the respective treatments, rats were anesthetized by injection of pentobarbital sodium (35-50 mg/kg ip). The soleus muscle, the gastrocnemius muscle, the red and white regions of the vastus lateralis muscle, and the liver were quickly removed and immediately frozen using stainless steel block clamps at liquid nitrogen temperature. Tissues were kept frozen at
80°C until
analyses. The epididymal and retroperitoneal fat pads were weighed as
an indicator of adiposity.
Antibodies.
Anti-
1, anti-
1, anti-
2,
and anti-phosphorylated ACC antibodies were purchased from Upstate
Biotechnology (Lake Placid, NY). Anti-
2,
anti-
1, anti-
2, and anti-
3
antibodies were prepared as described previously (7).
Muscle assays.
Muscles for determination of ACC and AMPK activity were ground to
powder under liquid nitrogen. The powder was weighed and homogenized (1 g muscle/9 ml buffer) in a buffer containing 100 mM
mannitol, 50 mM NaF, 10 mM Tris, 1 mM EDTA, 10 mM
-mercaptoethanol, pH 7.5, and proteolytic enzyme inhibitors (8 trypsin-inactivating units
aprotinin/l, 10 mg/l leupeptin, and 10 mg/l antitrypsin). The
homogenate was centrifuged at 48,000 g for 30 min. ACC was precipitated from the supernatant by addition of 144 mg ammonium sulfate/ml followed by stirring for 30 min on ice. The precipitate was
collected by centrifugation (48,000 g, 30 min). The pellet was dissolved in 10% of the original volume of the homogenate buffer,
and this solution was centrifuged again to remove insoluble protein.
ACC activity was determined on the supernatant at citrate/magnesium concentrations of 0-20 mM by measuring the rate of incorporation of [14C]bicarbonate into malonyl-CoA at 37°C for 10 min, as described previously (46). The ACC activity data
were fitted to the Hill equation using the Grafit program (Sigma, St.
Louis, MO). This program allows determination of the activation
constant for citrate (Ka) and the maximal
velocity as a function of citrate concentration (Vmax). AMPK activity was determined
(46) using the same resuspended ammonium sulfate
precipitate used to determine ACC activity. Neutralized perchloric acid
extracts of the gastrocnemius muscle were used for the determination of
malonyl-CoA (20). Glycogen content of the powdered muscle
was determined by the method of Passonneau and Lowry (26).
Immunoblotting for AMPK subunits and ACC.
Muscle was ground to powder under liquid nitrogen and homogenized
(1 g muscle/9 ml buffer) in a buffer containing 100 mM mannitol, 50 mM
NaF, 10 mM Tris, 1 mM EDTA, 10 mM
-mercaptoethanol, pH 7.5, and
proteolytic enzyme inhibitors (8 trypsin-inactivating units
aprotinin/l, 10 mg/l leupeptin, and 2 mg/l antitrypsin). The homogenate
was centrifuged at 700 g at 4°C for 10 min. The supernatant was diluted [1:2:1 (vol/vol/vol) homogenate-water-Laemmli buffer], and 40 µl of this solution were loaded onto the gel. Blots
for ACC and phosphorylated ACC were run using 5%
Tris · HCl Ready Gels (Bio-Rad, Hercules, CA).
The AMPK subunit blots were done using 7.5 or 10%
Tris · HCl Ready Gels. After SDS-PAGE (200 V for
40 min), proteins were transferred from gel to nitrocellulose membrane
(100 V for 50 min). Membranes were blocked in 5% nonfat dry milk
(Bio-Rad) in PBST (139 mM NaCl, 2.7 mM KH2PO4,
9.9 mM Na2HPO4, and 0.1% Tween 20) for 1 h and then incubated overnight with the specific antibodies to the AMPK
subunits or phosphorylated ACC in 5% nonfat dry milk in PBST.
After the membranes were washed twice with PBST and twice with PBS,
antibodies bound to the nitrocellulose membrane were detected with
anti-rabbit immunoglobulin-horseradish peroxidase (HRP)-linked antibody
(Amersham Pharmacia Biotech, Piscataway, NJ) or with donkey anti-sheep
HRP (in the case of the
2- and
3-subunits). The membrane designated for ACC
quantitation was exposed to streptavidin-HRP conjugate (Amersham
Pharmacia). After they were washed twice in PBST and twice in PBS (139 mM NaCl, 2.7 mM KH2PO4, and 9.9 mM
Na2HPO4), membranes were incubated with
enhanced chemiluminescence detection reagent and visualized on enhanced
chemiluminescence hyperfilm (Amersham Pharmacia Biotech). Relative
amounts of each protein were then quantified using a Hewlett-Packard
Scan Jet 5370C and SigmaGel software (SPSS, Chicago, IL). Extracts from
each treatment group were run on the same gel and blot. All data are
expressed relative to muscle extracts from the control group.
Statistical analysis. Values are means ± SE. Results of the four different treatment groups were compared using analysis of variance followed by Fisher's least significant differences test. Differences were considered to be statistically significant when P < 0.05.
| |
RESULTS |
|---|
|
|
|---|
Body weight, fat pad weight, food intake, malonyl-CoA, and glycogen. The final body weights were 298 ± 11, 255 ± 2, 289 ± 10, and 282 ± 7 g for control, PTU, T21d, and T7d rats, respectively. The mean of the PTU-treated group was significantly different from all others (P < 0.05). Food intake for the penultimate 2 days before the animals were killed was 26 ± 1, 17 ± 1, 35 ± 1, and 24 ± 1 g, respectively. The means for the PTU and T21d rats were significantly different from all others (P < 0.05). The combined mass of the epididymal and retroperitoneal fat pads expressed as percent body weight were 0.59 ± 0.03, 0.53 ± 0.02, 0.21 ± 0.04, 0.39 ± 0.06 for control, PTU, T21d, and T7d rats, respectively. Both thyroid hormone-treated groups had significantly reduced fat pad weight compared with control and PTU-treated rats (P < 0.05).
Malonyl-CoA content of the gastrocnemius muscle was significantly increased in PTU-treated rats and significantly reduced in thyroid hormone-treated rats compared with controls (Fig. 1). Glycogen content of gastrocnemius muscle and glucose and lactate concentrations of the blood were not markedly influenced by the thyroid hormone treatments (data not shown).
|
AMPK subunit isoform Western blots in skeletal muscle.
Figure 2 shows the Western blot data for
subunit isoforms of AMPK in gastrocnemius muscle. Subunit isoforms
migrated in the approximate positions as expected on the basis of
standards consisting of known molecular mass proteins (
-subunit at
63 kDa,
1-subunit at 32 kDa,
2-subunit at
30 kDa,
1-subunit at 35 kDa,
2-subunit at
63 kDa, and
3-subunit at 55 kDa). All subunit isoforms
were present in significantly greater amounts in T21d than in PTU rats. The direction of change appeared to be the same for all subunit isoforms. Table 1 demonstrates that the
pattern of expression in the red and white regions of the quadriceps
(composed of type IIa and IIb fibers, respectively) was similar to that
of the gastrocnemius (composed predominantly of type IIa and IIb
fibers). Although much greater variation occurred in the soleus, it
appeared that larger changes occurred in this muscle than in the type
IIa or IIb fast-twitch muscle fibers.
|
|
ACC activity, AMPK activity, ACC, and phosphorylated ACC Western
blots.
ACC activities as a function of citrate concentration are shown in Fig.
3. The Vmax values
were 26.4 ± 1.2, 20.0 ± 1.8, 39.9 ± 0.6, and
26.6 ± 2.5 nmol · g
1 · min
1
for control, PTU, T21d, and T7d rats, respectively (n = 5-6). The Vmax values for PTU and T21d rats
were significantly different from all other groups (P < 0.05). The Ka values were 5.6 ± 1.1, 5.6 ± 1.2, 4.6 ± 0.6, and 5.8 ± 1.5, respectively.
These values were not significantly different from one another. The
liver ACC activity was also determined for comparative purposes. The
Vmax values were 317 ± 48, 100 ± 15, and 495 ± 87 nmol · g
1 · min
1
for control, PTU, and T21d rats, respectively (n = 5-6). The values were significantly different from each other
(P < 0.05). The ACC activity appears to vary as a
function of thyroid state in both tissues, although the range of
Vmax activity was fivefold in liver and twofold
in muscle when PTU rats were compared with T21d rats. ACC activity data
from individual muscle types showed the same pattern as in the
gastrocnemius (Table 2).
|
|
1 · min
1
for control, PTU, T21d, and T7d rats, respectively. Although trends
were apparent between the PTU- and thyroid hormone-treated rats, these
values were not significantly different from one another.
Data from Western blots for ACC and phosphorylated ACC for
gastrocnemius muscle are shown in Fig. 4.
As with the ACC activity measurements, the amount of ACC was increased
in response to thyroid hormones. In addition, the amount of
phosphorylated ACC increased as a function of thyroid hormones. A
summary of these two measurements in the different muscle types is
shown in Table 3. Again, the pattern of
adaptation in the individual muscles types in response to varying
thyroid hormone treatment was similar to that of the mixed-fiber
gastrocnemius muscle.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
Previous studies have clearly demonstrated marked fiber type-specific adaptations of skeletal muscle in response to thyroid hormone treatment. Oxidative enzymes of the citric acid cycle, electron transport chain, ketone oxidation enzymes, hexokinase, and GLUT-4 increase in response to thyrotoxicosis (36, 43, 47). Contractile proteins and sarcoplasmic reticulum proteins, as well as contractile properties (soleus), change with thyroid state (5, 9, 10). Because AMPK is very likely involved in control of fatty acid oxidation, glucose uptake, and specific gene expression in skeletal muscle, it seemed reasonable that expression of AMPK subunit isoforms might also be regulated by thyroid state. This indeed proved to be the case. It appears that there is coordinated regulation of all subunits. For the most part, all subunits appear to be increasing in response to exposure to increasing levels of thyroid hormones. It will be interesting to determine whether all genes involved have thyroid response elements in their promoter regions. These studies do not provide information on the mechanism of the increase in total amounts of each subunit in response to thyroid hormones. This could be due to thyroid hormone-induced increased rate of transcription of the respective genes or to other mechanisms such as reduction in rate of mRNA or protein degradation.
One previous study reported a small downregulation of mRNA for an AMPK subunit in brain and thyroid of a hyperthyroid goat (27). It is unclear whether this is a tissue-specific adaptation or possibly a species difference.
Previous studies demonstrated that expression of citrate synthase and
other mitochondrial oxidative enzymes in response to thyroid hormones
is fiber type dependent (47). The soleus muscle (composed
predominantly of the slow-twitch, type I fibers) has been shown to
respond with much larger increases in mitochondrial oxidative enzymes
than did the fast-twitch high-oxidative (type IIa) and the fast-twitch
low-oxidative (type IIb) fibers (47). In the present
study, the change in expression of the AMPK subunits in response to PTU
and thyroid hormones in the red (type IIa fibers) and white (type IIb
fibers) regions of the quadriceps was similar to that observed in the
gastrocnemius, which consists predominantly of type IIa and IIb fibers.
Much larger changes were observed in the soleus, particularly in the
1-subunit (23-fold difference between the PTU and the
T21d group) and in the
3-subunit (10-fold difference
between the PTU and the T21d group). Although the specific roles of
different combinations of the different subunits have not been
ascertained, it is possible that intracellular targeting may be one
function of the
- and/or
-subunit isoforms.
The stimulatory effect of thyroid hormones on liver proteins involved in lipogenesis was described many years ago. Fatty acid synthetase, ACC, malic enzyme, and spot 14 protein show dramatic increases in liver in response to treatment of rats with thyroid hormones (4, 16, 30, 35, 37, 51). Muscle is not considered to be a lipogenic tissue, yet it contains significant amounts of a unique isoform of ACC (3, 11, 38, 41, 50). This isoform is thought to play a role in regulating rates of muscle fatty acid oxidation by controlling levels of malonyl-CoA, an inhibitor of CPT I (18, 19, 31). Muscle ACC is phosphorylated and inactivated by AMPK (activated in response to contraction) (25, 42, 45, 46, 49). The consequent decline in malonyl-CoA relieves inhibition of CPT I, allowing fatty acid oxidation to proceed. Little is known regarding control of expression of the muscle isoform of ACC. In a recent study, expression of ACC in rat skeletal muscle was not influenced by a rigorous program of training by treadmill running (7). Fasting and refeeding have marked effects on expression of liver lipogenic enzymes but not on ACC in the muscle (48). In the present study, the magnitude of differences in activity of ACC between PTU- and thyroid hormone-treated rats is much greater in liver than in skeletal muscle, but the direction of change is the same.
In vitro and in vivo studies have demonstrated that phosphorylation of muscle ACC by AMPK results in a shift of the citrate activation curve to the right (with consequent increase in Ka) and a decrease in Vmax (21, 22, 25, 46, 49). This results in a decrease in ACC activity, particularly at physiological concentrations of citrate. Although the amount of ACC phosphorylated in the site equivalent to serine 79 of the liver isoform (serine 221 in the human muscle isoform) was increased in the present study in response to the increase in thyroid hormones, the kinetic properties of ACC determined in enzyme activity measurements were not altered. This provides evidence that the same proportion of the total ACC was phosphorylated. We would have expected an increase in the measured Ka if a greater proportion of the total ACC were phosphorylated by AMPK in the rats given excess thyroid hormones. It appears that the increase in absolute amount of phosphorylated ACC was proportional to the increase in total ACC protein.
It is conceivable that AMPK activation in response to thyroid hormone could mediate some of the effects on metabolism, stimulating an increase in glucose uptake and an increase in fatty acid oxidation to support the elevated rate of energy consumption. AMPK activity, although tending to be higher in the thyroid hormone-treated rats, was not significantly increased. It should be pointed out that, with intraperitoneal injection of pentobarbital for anesthesia, some variability occurs in the time to surgical level of anesthesia. This may account for some of the variability in muscle AMPK response. It is unlikely that thyroid hormones would directly activate AMPK, since most thyroid hormone effects are thought to be mediated by regulation of gene transcription, but it is possible that AMPK could be activated secondarily to the increase in metabolic rate. High-energy phosphates do not appear to be markedly influenced (in soleus muscle) at this level of hyperthyroidism, however (43).
ACC activity and ACC protein (quantified by Western blot) were significantly higher in muscle of thyroid hormone-treated rats than in muscle of control or PTU-treated rats. The malonyl-CoA content, however, was highest in the PTU-treated rats and lowest in the thyroid hormone-treated rats. This implies that the malonyl-CoA content of the muscle of rats in these treatment groups is determined by mechanisms other than long-term changes in muscle content of ACC. Possible means of regulation include cytoplasmic citrate concentration (allosteric activator of ACC), long-chain acyl-CoA (allosteric inhibitor of ACC) concentration, and phosphorylation state. Although a greater absolute amount of ACC was phosphorylated in the muscle of thyroid hormone-treated rats, the shape of the citrate activation curve was not significantly changed, implying that substrate supply or short-term allosteric mechanisms were more important in determining malonyl-CoA content of the muscle in rats of different thyroid hormone status. Whatever the mechanism, the lower muscle malonyl-CoA in thyroid hormone-treated rats would be expected to result in an increase in rate of long-chain fatty acid oxidation. With the hypermetabolic state extending to 3 wk, a 64% reduction in epididymal fat pad weight was observed in the face of a 35% increase in food intake. This implies a marked increase in fat oxidation in response to excess thyroid hormones. A knockout mouse lacking muscle ACC exhibited increased rate of muscle fat oxidation and reduced body fat content (1). In human subjects, experimentally induced mild hyperthyroidism results in a significant reduction in total fat stores within 6-9 wk (17).
A previous study from our laboratories indicated an association between
the training-induced increase in
3-subunit expression and increased muscle glycogen content (7). The fact
that no difference in muscle glycogen content was observed between PTU- and thyroid hormone-treated rats, despite a significant difference in
3-subunit expression, indicates that there may be no
cause-and-effect relationship. It is recognized that numerous factors
may influence muscle glycogen content.
In summary, expression of AMPK subunits and ACC in skeletal muscle is greater in rats treated with excess thyroid hormone than in rats treated with PTU to inhibit thyroid activity. In general, the same pattern is seen in slow-twitch red (type I), fast-twitch red (type IIa), and fast-twitch white (type IIb) fibers. To our knowledge, this is the first indication that thyroid state influences expression of AMPK and ACC in skeletal muscle.
| |
ACKNOWLEDGEMENTS |
|---|
This study was supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases Grant AR-41438 (to W. W. Winder) and by Project Grant RD99/0001901 from Diabetes UK (to D. G. Hardie). S. R. Paulsen and S. R. Gammon were supported in part by an undergraduate student mentoring grant from the College of Biological and Agricultural Sciences, Brigham Young University. K. J. Mustard was supported by a studentship from the Biotechnology and Biological Sciences Research Council (UK) and by a grant from Novo-Nordisk.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: W. W. Winder, 545 WIDB, Dept. of Physiology and Developmental Biology, Brigham Young University, Provo, UT 84602 (E-mail: william_winder{at}byu.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/japplphysiol.00504.2002
Received 11 June 2002; accepted in final form 30 July 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Abu-Elheiga, L,
Matzuk MM,
Abo-Heshema KA,
and
Wakil SJ.
Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2.
Science
291:
2558-2559,
2001
2.
Beri, RK,
Marley AE,
Gee CG,
Sopwith WF,
Aguan K,
Carling D,
and
Carey F.
Molecular cloning, expression and chromosomal localization of human AMP-activated protein kinase.
FEBS Lett
356:
117-121,
1994[Web of Science][Medline].
3.
Bianchi, A,
Evans JL,
Iverson AJ,
Nordlund A,
Watts TD,
and
Witters LA.
Identification of an isozymic form of acetyl-CoA carboxylase.
J Biol Chem
265:
1502-1509,
1990
4.
Blennemann, B,
Leahy P,
Kim TS,
and
Freake HC.
Tissue-specific regulation of lipogenic mRNAs by thyroid hormone.
Mol Cell Endocrinol
110:
1-8,
1995[Web of Science][Medline].
5.
Caiozzo, VJ,
Haddad F,
Baker M,
McCue S,
and
Baldwin KM.
MHC polymorphism in rodent plantaris muscle: effects of mechanical overload and hypothyroidism.
Am J Physiol Cell Physiol
278:
C709-C717,
2000
6.
Carling, D,
Clarke PR,
Zammit VA,
and
Hardie DG.
Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities.
Eur J Biochem
186:
129-136,
1989[Web of Science][Medline].
7.
Durante, PE,
Mustard KJ,
Park SH,
Winder WW,
and
Hardie DG.
Effects of endurance training on activity and expression of AMP-activated protein kinase isoforms in rat muscles.
Am J Physiol Endocrinol Metab
283:
E178-E186,
2002
8.
Fisher, JS,
Gao J,
Han DH,
Holloszy JO,
and
Nolte LA.
Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin.
Am J Physiol Endocrinol Metab
282:
E18-E23,
2002
9.
Fitts, RH,
Winder WW,
Brooke MH,
Kaiser KK,
and
Holloszy JO.
Contractile, biochemical, and histochemical properties of thyrotoxic rat soleus muscle.
Am J Physiol Cell Physiol
238:
C15-C20,
1980
10.
Fitzsimons, DP,
Herrick RE,
and
Baldwin KM.
Isomyosin distributions in rodent muscles: effects of altered thyroid state.
J Appl Physiol
69:
321-327,
1990
11.
Ha, J,
Lee JK,
Kim KS,
and
Witters LA.
Cloning of human acetyl-CoA carboxylase-
and its unique features.
Proc Natl Acad Sci USA
93:
11466-11470,
1996
12.
Hardie, DG,
and
Carling D.
The AMP-activated protein kinase. Fuel gauge of the mammalian cell.
Eur J Biochem
246:
259-273,
1997[Web of Science][Medline].
13.
Hardie, DG,
Salt IP,
and
Davies SP.
Analysis of the role of the AMP-activated protein kinase in the response to cellular stress.
Methods Mol Biol
99:
63-74,
2000[Medline].
14.
Hawley, SA,
Davison Woods A,
Davies SP,
Beri RK,
Carling D,
and
Hardie DG.
Characterization of the AMP-activated protein kinase kinase from rat liver, and identification of threonine-172 as the major site at which it phosphorylates and activates AMP-activated protein kinase.
J Biol Chem
271:
27879-27887,
1996
15.
Jakobsen, SN,
Hardie DG,
Morrice N,
and
Tornqvist HE.
5'-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside.
J Biol Chem
276:
46912-46916,
2001
16.
Kinlaw, WB,
Tron P,
and
Witters LA.
Thyroid and dietary carbohydrate induce different hepatic zonation of both "spot 14" and acetyl-coenzyme-A carboxylase: a novel mechanism of coregulation.
Endocrinology
133:
645-650,
1993
17.
Lovejoy, JC,
Smith SR,
Bray GA,
DeLany JP,
Rood JC,
Gouvier D,
Windhauser M,
Ryan DH,
Macchiavelli R,
and
Tulley R.
A paradigm of experimentally induced mild hyperthyroidism: effects on nitrogen balance, body composition, and energy expenditure in healthy young men.
J Clin Endocrinol Metab
82:
765-770,
1997
18.
McGarry, JD.
Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes.
Diabetes
51:
7-18,
2002
19.
McGarry, JD,
and
Brown NF.
The mitochondrial carnitine palmitoyltransferase system from concept to molecular analysis.
Eur J Biochem
244:
1-14,
1997[Web of Science][Medline].
20.
McGarry, JD,
Stark MJ,
and
Foster DW.
Hepatic malonyl-CoA levels of fed, fasted, and diabetic rats as measured using a simple radioisotopic assay.
J Biol Chem
253:
8291-8293,
1978
21.
Merrill, GF,
Kurth EJ,
Hardie DG,
and
Winder WW.
AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle.
Am J Physiol Endocrinol Metab
273:
E1107-E1112,
1997
22.
Merrill, GF,
Kurth EJ,
Rasmussen BB,
and
Winder WW.
Influence of malonyl-CoA and palmitate concentration on rate of palmitate oxidation in rat muscle.
J Appl Physiol
85:
1909-1914,
1998
23.
Mu, J,
Brozinick JT,
Valladares O,
Bucan M,
and
Birnbaum MJ.
A role for AMP-activated protein kinase in contraction and hypoxia regulated glucose transport in skeletal muscle.
Mol Cell
7:
1085-1094,
2001[Web of Science][Medline].
24.
Ojuka, EO,
Jones TE,
Nolte LA,
Chen M,
Wamhoff BR,
Sturek M,
and
Holloszy JO.
Regulation of GLUT-4 biogenesis in muscle: evidence for involvement of AMPK and Ca2+.
Am J Physiol Endocrinol Metab
282:
E1008-E1013,
2002
25.
Park, SH,
Gammon SR,
Knippers JD,
Paulsen SR,
Rubink DS,
and
Winder WW.
Phosphorylation-activity relationships of AMP-activated protein kinase and acetyl-CoA carboxylase in muscle.
J Appl Physiol
92:
2475-2482,
2002
26.
Passonneau, JV,
and
Lowry OH.
Enzymatic Analysis: A Practical Guide. Totowa, NJ: Humana, 1993, p. 177-178.
27.
Piosik, PA,
van Goenigen M,
Ponne NJ,
Valentijn LJ,
Bolhuis PA,
and
Baas F.
Caprine homologue of rodent 5'-AMP-activated protein kinase subunit and yeast SNF4/CAT3 is down-regulated by thyroid hormone.
Brain Res Mol Brain Res
40:
240-253,
1996[Medline].
28.
Ponticos, M,
Lu QL,
Morgan JE,
Hardie DG,
Partridge TA,
and
Carling D.
Dual regulation of the AMP-activated protein kinase provides a novel mechanism for the control of creatine kinase in skeletal muscle.
EMBO J
17:
1688-1699,
1998[Web of Science][Medline].
29.
Richardson, JM,
and
Pessin JE.
Identification of a skeletal muscle specific regulatory domain in the rat GLUT4/muscle-fat gene.
J Biol Chem
268:
21021-21027,
1993
30.
Roncari, DA,
and
Murthy VK.
Effects of thyroid hormones on enzymes involved in fatty acid and glycerolipid synthesis.
J Biol Chem
250:
4134-4138,
1975
31.
Ruderman, NB,
Saha AK,
Vavvas D,
and
Witters LA.
Malonyl-CoA, fuel sensing, and insulin resistance.
Am J Physiol Endocrinol Metab
276:
E1-E18,
1999
32.
Stapleton, D,
Woollatt E,
Mitchelhill KI,
Nicholl JK,
Fernandez CS,
Michell BJ,
Witters LA,
Power DA,
Sutherland GR,
and
Kemp BE.
AMP-activated protein kinase isoenzyme family: subunit structure and chromosomal location.
FEBS Lett
409:
452-456,
1997[Web of Science][Medline].
33.
Stein, SC,
Woods A,
Jones NA,
Davison MD,
and
Carling D.
The regulation of AMP-activated protein kinase by phosphorylation.
Biochem J
345:
437-443,
2000[Web of Science][Medline].
34.
Stephens, TJ,
Chen ZP,
Canny BJ,
Michell BJ,
Kemp BE,
and
McConell GK.
Progressive increase in human skeletal muscle AMPK
2 activity and ACC phosphorylation during exercise.
Am J Physiol Endocrinol Metab
282:
E688-E694,
2002
35.
Swierczynski, J,
Mitchell DA,
Reinhold DS,
Salati LM,
Stapleton SR,
Klautky SA,
Struve AE,
and
Goodridge AG.
Triiodothyronine-induced accumulations of malic enzyme, fatty acid synthase, acetyl-coenzyme A carboxylase, and their mRNAs are blocked by protein kinase inhibitors. Transcription is the affected step.
J Biol Chem
266:
17459-17466,
1991
36.
Torrance, CJ,
Devente JE,
Jones JP,
and
Dohm GL.
Effects of thyroid hormone on GLUT4 glucose transporter gene expression and NIDDM in rats.
Endocrinology
138:
1204-1214,
1997
37.
Towle, HC,
and
Mariash CN.
Regulation of hepatic gene expression by lipogenic diet and thyroid hormone.
Fed Proc
45:
2406-2411,
1986[Web of Science][Medline].
38.
Trumble, GE,
Smith MA,
and
Winder WW.
Purification and characterization of rat skeletal muscle acetyl-CoA carboxylase.
Eur J Biochem
231:
192-198,
1995[Web of Science][Medline].
39.
Vavvas, D,
Apazidis A,
Saha AK,
Gamble J,
Patel A,
Kemp BE,
Witters LA,
and
Ruderman NB.
Contraction-induced changes in acetyl-CoA carboxylase and 5'-AMP-activated kinase in skeletal muscle.
J Biol Chem
272:
13256-13261,
1997.
40.
Verhoeven, AJM,
Woods A,
Brennan CH,
Hawley SA,
Hardie DG,
Scott J,
Beri RK,
and
Carling D.
The AMP-activated protein kinase gene is highly expressed in rat skeletal muscle.
Eur J Biochem
228:
236-243,
1995[Web of Science][Medline].
41.
Widmer, J,
Fassihi KS,
Schlichter SC,
Wheeler KS,
Crute BE,
King N,
Nutile-McMenemy N,
Noll WW,
Daniel S,
Ha J,
Kim KH,
and
Witters LA.
Identification of a second human acetyl-CoA carboxylase gene.
Biochem J
316:
915-922,
1996[Medline].
42.
Winder, WW.
Energy sensing and signaling by AMP-activated protein kinase in skeletal muscle.
J Appl Physiol
91:
1017-1028,
2001
43.
Winder, WW.
Time course of the T3- and T4-induced increase in rat soleus muscle mitochondria.
Am J Physiol Cell Physiol
236:
C132-C138,
1979
44.
Winder, WW,
Arogyasami J,
Elayan IM,
and
Cartmill D.
Time course of the exercise-induced decline in malonyl-CoA in different muscle types.
Am J Physiol Endocrinol Metab
259:
E266-E271,
1990
45.
Winder, WW,
and
Hardie DG.
AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes.
Am J Physiol Endocrinol Metab
277:
E1-E10,
1999
46.
Winder, WW,
and
Hardie DG.
Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise.
Am J Physiol Endocrinol Metab
270:
E299-E304,
1996
47.
Winder, WW,
and
Holloszy JO.
Response of mitochondria of different types of skeletal muscle to thyrotoxicosis.
Am J Physiol Cell Physiol
232:
C180-C184,
1977
48.
Winder, WW,
MacLean PS,
Lucas JC,
Fernley JE,
and
Trumble GE.
Effect of fasting and refeeding on acetyl-CoA carboxylase in rat hindlimb muscle.
J Appl Physiol
78:
578-582,
1995
49.
Winder, WW,
Wilson HA,
Hardie DG,
Rasmussen BB,
Hutber CA,
Call GB,
Clayton RD,
Conley LM,
Yoon S,
and
Zhou B.
Phosphorylation of rat muscle acetyl-CoA carboxylase by AMP-activated protein kinase and protein kinase A.
J Appl Physiol
82:
219-225,
1997
50.
Witters, LA,
Widmer J,
King AN,
Fassihi K,
and
Kuhajda F.
Identification of human acetyl-CoA carboxylase isozymes in tissue and in breast cancer cells.
Int J Biochem
26:
589-594,
1994[Web of Science][Medline].
51.
Zhang, Y,
Yin L,
and
Hillgartner FB.
Thyroid hormone stimulates acetyl-CoA carboxylase-
transcription in hepatocytes by modulating the composition of nuclear receptor complexes bound to a thyroid response element.
J Biol Chem
276:
974-983,
2001
52.
Zheng, D,
MacLean PS,
Pohnert SC,
Knight JB,
Olson AL,
Winder WW,
and
Dohm GL.
Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase.
J Appl Physiol
91:
1073-1083,
2001
This article has been cited by other articles:
![]() |
D. J. Branvold, D. R. Allred, D. J. Beckstead, H. J. Kim, N. Fillmore, B. M. Condon, J. D. Brown, S. N. Sudweeks, D. M. Thomson, and W. W. Winder Thyroid hormone effects on LKB1, MO25, phospho-AMPK, phospho-CREB, and PGC-1{alpha} in rat muscle J Appl Physiol, October 1, 2008; 105(4): 1218 - 1227. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Summermatter, D. Mainieri, A. P. Russell, J. Seydoux, J. P. Montani, A. Buchala, G. Solinas, and A. G. Dulloo Thrifty metabolism that favors fat storage after caloric restriction: a role for skeletal muscle phosphatidylinositol-3-kinase activity and AMP-activated protein kinase FASEB J, March 1, 2008; 22(3): 774 - 785. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jing and F. Ismail-Beigi Role of 5'-AMP-activated protein kinase in stimulation of glucose transport in response to inhibition of oxidative phosphorylation Am J Physiol Cell Physiol, February 1, 2006; 290(2): C484 - C491. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Frosig, S. B. Jorgensen, D. G. Hardie, E. A. Richter, and J. F. P. Wojtaszewski 5'-AMP-activated protein kinase activity and protein expression are regulated by endurance training in human skeletal muscle Am J Physiol Endocrinol Metab, March 1, 2004; 286(3): E411 - E417. [Abstract] [Full Text] |
||||
![]() |
I. Irrcher, P. J. Adhihetty, T. Sheehan, A.-M. Joseph, and D. A. Hood PPARgamma coactivator-1alpha expression during thyroid hormone- and contractile activity-induced mitochondrial adaptations Am J Physiol Cell Physiol, June 1, 2003; 284(6): C1669 - C1677. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |